The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) alone or in combination with high dose interferon-alfa (HDI) in advanced melanoma (E3611).
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Prometheus (Inst)
 
Sandra J. Lee
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks (I)
Consulting or Advisory Role - Roche/Genentech
 
Uma N. M. Rao
No Relationships to Disclose
 
Arun Nagarajan
No Relationships to Disclose
 
Mark R. Albertini
No Relationships to Disclose
 
Jerry W Mitchell
No Relationships to Disclose
 
Stuart J. Wong
Research Funding - Novartis
 
Mark A. Taylor
No Relationships to Disclose
 
Noel Laudi
Employment - Minnesota Oncology
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Merck
Consulting or Advisory Role - Alexion Pharmaceuticals; Bristol-Myers Squibb; Merck
Speakers' Bureau - Bristol-Myers Squibb; Merck
 
Phu Van Truong
No Relationships to Disclose
 
Robert Martin Conry
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Checkmate Pharmaceuticals; GreenPeptide; Novartis; Roche; Solaran RX
Research Funding - Merck (Inst); Prometheus (Inst)